PDCD1 and cancer: A clinical trial of the anti-PD-1 antibody pembrolizumab in patients with HIV on anti-retroviral therapy and advanced-stage cancer, reported that pembrolizumab did not impair CD4+ cell counts or viral suppression [12, 13].